logo
Grupo Bimbo sets out Mexico-wide capex plans

Grupo Bimbo sets out Mexico-wide capex plans

Yahoo7 days ago
Mexican bakery giant Grupo Bimbo plans to make investments worth more than $2bn across seven states in its domestic market through 2028.
Baja California, Yucatán, Mexico City, Nuevo León, Querétaro, Puebla, and the State of Mexico will benefit from the Grupo Bimbo projects, according to a government statement, which did not identify the specific plants operated by the company to receive the investments.
The programme will generate more than 2,000 direct jobs and 10,800 indirect jobs, the government said.
Under the government's Plan Mexico initiative, José Manuel González Guzmán, the president of Grupo Bimbo's operations in Mexico, outlined in the same statement how the investment "aims to increase the productive and technological capacity of its various plants, modernise its fleet of electric delivery vehicles, [and] promote the circular economy with sustainable packaging".
He was quoted as saying: "I believe that Mexico, with this Plan Mexico, will continue to grow in the coming years. This alliance we have, this strengthening of the economy, we must have confidence in it."
Grupo Bimbo had not responded to Just Food's request for more details on the planned investment projects and the facilities involved at the time of writing.
Ximena Escobedo Juárez, head of the Productive Development Unit and the Office of the Ministry of Economy, listed the municipalities in Mexico that will benefit from the investments.
They are: Mexicali and Tijuana in Baja California; Mérida in Yucatán; Azcapotzalco in Mexico City; Salinas Victoria in Nuevo León; El Marqués in Querétaro; the capital of Puebla; and Toluca and Lerma in the State of Mexico.
Meanwhile, Reuters' coverage of the investment programme last week also included comments from González on US tariffs, made during a press conference by Mexico President Claudia Sheinbaum.
"We believe that we will not be affected if any tariffs are imposed by the US," González was quoted as saying by the news agency.
Elsewhere, Grupo Bimbo has been expanding through M&A. It struck an acquisition for packaged breads supplier Karamolegos Bakery Romania, based in Ilfov, Bucharest, earlier this year.
And late last year, it snapped up Slovenia bakery business Don Don. The company also struck an acquisition in Brazil last September for the bakery group Wickbold.
Posting its first-quarter results in April, Grupo Bimbo said net sales reached a 'record' of 103.7bn pesos ($5.5bn), or 10.8% growth year-on-year.
In Mexico, Q1 sales rose 1.7% to 38bn pesos.
Group operating income dropped 1.8% to 6.5bn pesos, while adjusted EBITDA rose 8% to 12.8bn pesos. Net income declined 26.6% to 1.7bn pesos.
It was a mixed bag of results for the 2024 fiscal year. Net sales rose 2.1% to 408.3bn pesos, while operating income decreased 6.5% to 33.1bn pesos.
Adjusted EBITDA climbed 1% to 55.4bn pesos but net income retreated 18.9% to 12.5bn pesos.
"Grupo Bimbo sets out Mexico-wide capex plans" was originally created and published by Just Food, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UAE Opens Golden Visa Path to Investors Without Sponsorship
UAE Opens Golden Visa Path to Investors Without Sponsorship

Entrepreneur

time19 minutes ago

  • Entrepreneur

UAE Opens Golden Visa Path to Investors Without Sponsorship

You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. In a significant move to attract global talent and long-term investment, the United Arab Emirates has simplified the process for investors to obtain the coveted Golden Visa—now available without the need for a local sponsor. The announcement, made by the Federal Authority for Identity, Citizenship, Customs and Port Security (ICP), outlines a streamlined, eight-step application procedure aimed at facilitating business and economic growth. Previously, the 10-year Golden Residency Visa often required backing by a company or government entity. Under the new system, investors and business owners can apply independently, making the UAE even more attractive to international entrepreneurs and high-net-worth individuals seeking stability, access to regional markets, and tax advantages. Applicants must provide proof of a minimum AED 2 million investment in the country through real estate, business capital, or public projects. They are also required to submit supporting documents, such as audited financial statements and proof of income, alongside a valid passport. The revised pathway is part of the UAE's broader efforts to diversify its economy and strengthen its position as a global business hub. By removing barriers to long-term residency, authorities hope to retain top talent, boost local investment, and encourage innovation in sectors like technology, finance, and renewable energy. Since its inception in 2019, the Golden Visa has been a cornerstone of the UAE's residency reform strategy. Expanding eligibility and easing procedural constraints signals a deeper commitment to economic openness and global competitiveness. Investors can initiate their application online through the ICP portal, with most approvals expected within a few weeks, pending background and security checks. With this policy shift, the UAE reinforces its image not just as a transit economy—but as a destination for long-term investment and high-impact entrepreneurship.

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Yahoo

timean hour ago

  • Yahoo

Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Yahoo

timean hour ago

  • Yahoo

Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target

Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store